Astatine has no commodity-scale supply chain. Every isotope is radioactive, and the longest-lived adopted nuclide in NNDC ENSDF, At-210, lasts only 8.1 hours. In atlas terms that makes astatine a research-only element: there is nothing to mine, refine, warehouse, or quote by tonne. What exists instead is a tightly time-constrained isotope service centered on At-211, the alpha emitter used in targeted radiopharmaceutical research.

The current operating model is essentially cyclotron-to-clinic logistics. The original 1940 Berkeley synthesis used alpha bombardment of bismuth, and the same basic nuclear reaction family still underlies modern At-211 production. DOE NIDC's current product information shows special-order, non-cGMP At-211 supplied from the University of Washington or Texas A&M University, in either sodium astatide solution or a 3-octanone column, with sale units in millicuries rather than mass.

Recent 2025 NIDC updates show progress, not industrialization. Automated processing at Texas A&M improved recovery speed and yield, and the first U.S. shipment of an astatine-labeled compound demonstrated a more clinically useful transport format. Even so, astatine remains a short-lived, geographically narrow accelerator product whose economic reality is research and early-stage therapeutic development rather than a commercial element market.